Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 198  
This article has been cited by
1Radionuclide Therapy for Bone Metastases
Hojjat Ahmadzadehfar,Markus Essler,Kambiz Rahbar,Ali Afshar-Oromieh
PET Clinics.2018;13(4)491
[DOI]
2177Lu/153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases
Mehrosadat Alavi,Farnaz Khajeh-Rahimi,Hassan Yousefnia,Mohammad Mohammadianpanah,Samaneh Zolghadri,Ali Bahrami-Samani,Mohammad Ghannadi-Maragheh
Cancer Biotherapy and Radiopharmaceuticals.2019;34(5)280
[DOI]
3177Lu/153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases
Manfred Fischer,Norbert Czech,Willm Uwe Kampen
Cancer Biotherapy and Radiopharmaceuticals.2018;34(5)1
[DOI]
4177Lu/153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases
Abdelhamid H. Elgazzar
Cancer Biotherapy and Radiopharmaceuticals.2017;34(5)387
[DOI]
5177Lu/153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases
Manfred Fischer,Norbert Czech,Willm Uwe Kampen
Cancer Biotherapy and Radiopharmaceuticals.2019;34(5)269
[DOI]
6Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on ß-Emitting and a-Emitting Radionuclides
Alireza Sadremomtaz,Mahboubeh Masoumi
Journal of Medical Imaging and Radiation Sciences.2019;50(2)272
[DOI]
7Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases
Rogier Lange,Rob ter Heine,Russ (FF) Knapp,John M.H. de Klerk,Haiko J. Bloemendal,N. Harry Hendrikse
Bone.2016;91(2)159
[DOI]
8Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases
Ambreen Khawar,Elisabeth Eppard,Frank Roesch,Hojjat Ahmadzadehfar,Stefan Kürpig,Michael Meisenheimer,Florian. C. Gaertner,Markus Essler,Ralph. A. Bundschuh
Annals of Nuclear Medicine.2019;33(6)404
[DOI]
9Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran
Amir Reza Jalilian,Davood Beiki,Arman Hassanzadeh-Rad,Arash Eftekhari,Parham Geramifar,Mohammad Eftekhari
Seminars in Nuclear Medicine.2016;46(4)340
[DOI]
10Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran
Manfred Fischer,Norbert Czech,Willm Uwe Kampen
Seminars in Nuclear Medicine.2019;46(4)1
[DOI]
11Estimated human absorbed dose of 177Lu–BPAMD based on mice data: Comparison with 177Lu–EDTMP
Hassan Yousefnia,Samaneh Zolghadri,Saeed Shanehsazzadeh
Applied Radiation and Isotopes.2015;104(4)128
[DOI]
12Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy
Ana M Denis-Bacelar,Sarah J Chittenden,V Ralph McCready,Antigoni Divoli,David P Dearnaley,Joe M O’Sullivan,Bernadette Johnson,Glenn D Flux
The British Journal of Radiology.2018;104(4)20170795
[DOI]
13Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results
Ambreen Khawar,Elisabeth Eppard,Frank Roesch,Hojjat Ahmadzadehfar,Stefan Kürpig,Michael Meisenheimer,Florian. C. Gaertner,Markus Essler,Ralph. A. Bundschuh
EJNMMI Research.2019;9(1)20170795
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal